Omapatrilat

N/A

Report date: 2022/07/18 15:43:45
NME

Base Information

Drug NameOmapatrilat
Drug Alias Name奥马屈拉omapatrilatomapatrilate奥帕曲拉omapatrilatum +[9] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionAngiotensin-converting enzyme inhibitorsNeprilysin inhibitors
TargetsAngiotensin-converting enzymeNeprilysin
Therapy Area/IndicationsCardiovascular DiseasesRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Wisconsin-Madison
Active IndicationsN/A
Inactive IndicationsCardiovascular DiseasesRenal Insufficiency, Chronic

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG